medigraphic.com

2004, Number 1

<< Back Next >>

Rev Hosp Jua Mex 2004; 71 (1)

Un modelo de atención a pacientes con diabetes mellitus tipo 2

Ramírez AJ

Language: Spanish
References: 30
Page: 18-26
PDF size: 467.71 Kb.


ABSTRACT

Diabetes is a disease with two components: genetic and environmental, but the former needs the presence of the latter (inadequate feeding behavior and life style) to be expressed phenotypicaly. Consequently, it is essential that patient be compromised to change past feeding behavior. This is accomplished through an efficient relationship between physician and patient using certain cognitivebehavioral principles. Moreover, the fast relief of symptomatology is a powerful tool for the cooperation of the patient. Besides, trivalent chromium (glucose tolerance factor) is used in order to sensitize target organs to insulin, as several clinical trials have shown. Very importantly, a patent pending drug that abolishes oxidative stress in the pancreas in order to produce more insulin is administered. Presently, 20 patients have a follow-up for the next 6 months after their last medical visit, because they are symptomless, without oral agents or insulin, normal diet and normal glucose levels on several occasions. This situation is called permanent and total control of diabetes, inasmuch as the patient remains with his new habits, perform daily exercise and ingest trivalent chromium on a permanent basis.


REFERENCES

  1. American Diabetes Association. Economic cost of diabetes in the U.S in 2002. Diabetes Care 2003; 26(3): 917-32.

  2. Carnevale GP, Rosi A, Sainaghi. Diabetes Care; 2003.

  3. Malik RA. The common pathophysiology of diabetic microvascular complications.

  4. Rome SJ. Biol Chem 2003; 278-20: 18063-8.

  5. Yim SJ. Biol Chem 2003; 278-20: 38260-8.

  6. Harrison’s. Principles of internal medicine. 15th Ed. 2001; 2: 2116.

  7. Philippe P. Chaos, population biology and epidemiology. Human Biol 1993; 65: 525-46.

  8. Yang J. Insulin stimulated cytosol alkalinization facilitates activation of glucose. Am J Physiol Endocrinol Metab; 2002.

  9. Tahmasebi M. The tissue angiotensin system in human pancreas. J Endocrinol 1999; 161: 317-22.

  10. Williamson JR. Glucotoxicity and diabetic vascular disease. Medical Dialogue on Diabetes 1989; 8: 8-10.

  11. Duplain H. Insulin resistance, hyperlipidemia and hipertension in mice lacking endotelial nitric oxide synthasa. Circulation 2001; 104: 342-5.

  12. Lenaz G. Role of mitochondria in oxidative stress and ageing. Biochim Biophys Acta 1998; 1366: 53-67.

  13. Ye JM, Lim-Fraser M. Evidence that amylin stimulates lypolisis in vivo: a possible mediator of insulin resistance. Amm J Physiol Endocrinol Met 2001; 280: E562-E569.

  14. Hayden MR. Atherosclerosis and plaque angiogenesis. Pathology and clinical classification of vulnerable plaque VP. Org 2001, 3.

  15. Hayden MR. Arteriogenesis and angiogenesis within unstable atherosclerotic plaques. Curr Interv Cardiol Rep 2000; 3: 218-27.

  16. McGarry JD. Banting Lecture 2001. Disregulation of fatty metabolism in the etiology of type 2 diabetes.

  17. Grundy SM. Hypertrigliceridemia, aterogenic dyslipidemia and metabolic syndrome. Am J Cardiol 1998; 81: 18-25B.

  18. Shimabukurg M. Fatty acids induce beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998; 95: 2498-2502.

  19. Folly F. Cross-talk between insulin and angiotensin II signaling system. Exp Clin Endocrinol diabetes 1999; 107: 133-9.

  20. Ross R. Atherosclerosis and inflammatory disease. N England J Med 1999; 340(2): 115-26.

  21. Fu MX. Glycation, glycosidation and cross linking of collagen by glucose. Diabetes 1994; 43: 676-83.

  22. Griendling KK. NAD(P)M oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.

  23. American Diabetes Association. Cross talk between iron metabolism and diabetes. Diabetes 2002; 51(8): 2348-54.

  24. Jacques PF. Relation between folate status, a common mutation in methylentetrahydrofolate reductase and plasma homocysteine concentration. Circulation 1996; 93: 7-9.

  25. Vemura S. Diabetes mellitus enhances vascular matrix of metalloproteinase activity: role of oxidative stress. Circ Res 2001; 88: 1291-8.

  26. McCook A. Short sleepers have higher diabetes risk. Diabetes Care 2003; 26: 380-4.

  27. Vincent JB. The biochemistry of chromium. A Soc Nutr Scien 2000; 715-18.

  28. Chromium and diabetes Workshop summary. Natcher Conference Center, National Institutes of Health 1999.

  29. Chromium. Harrison’s. Principles of internal medicine. 15th Ed. 2001: 29.

  30. Rosenzweig J, Wender R. Efficient management of diabetes. Patient Care 2002: p. 53-63.




2020     |     www.medigraphic.com